Combination therapy using three agents, namely anti-tau oligomer and anti-TfR bispecific mAbs, AN-1792, and MSCs, could be an extraordinarily effective and economical method for the treatment of mild-to-moderate dementia in AD patients. Here, TFRC is linked to dementia.